Sign In
Buy RLFTY
$0.423
+0 (+0%)
At Close: Jun 03, 2026
Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032
02:20am, Wednesday, 29'th Oct 2025
RLF-OD032 demonstrated bioequivalence to KUVAN® Powder Study results support planned 505(b)(2) NDA submission in early 2026 GENEVA, SWITZERLAND / ACCESS Newswire / October 29, 2025 / RELIEF THERAPEUT
Relief Therapeutics Publishes 2025 Half-Year Report
01:20am, Thursday, 14'th Aug 2025
GENEVAD, SE / ACCESS Newswire / August 14, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering inno
Relief Therapeutics Advances Publication of 2025 Half-Year Report
01:20am, Monday, 11'th Aug 2025
GENEVA, SWITZERLAND / ACCESS Newswire / August 11, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to deliver
Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze
01:20am, Tuesday, 29'th Jul 2025
NeuroX recently acquired the assets and operations of MindMaze, a world-renowned leader in evidence-based neurotherapeutic solutions for neurological diseases and brain disorders Business combination
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
01:20am, Friday, 20'th Jun 2025
GENEVA, SWITZERLAND / ACCESS Newswire / June 20, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief or the Company), a biopharmaceutical company committed to delivering
Relief Therapeutics Announces Results of Annual General Meeting
06:17am, Thursday, 12'th Jun 2025
Shareholders approved all proposals by a large majority GENEVA, SWITZERLAND / ACCESS Newswire / June 12, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief Therapeutics,
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
01:20am, Thursday, 22'nd May 2025
GENEVA, SWITZERLAND / ACCESS Newswire / May 22, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief or the Company), a biopharmaceutical company committed to delivering
Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
01:20am, Thursday, 15'th May 2025
GENEVA, SWITZERLAND / ACCESS Newswire / May 15, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief), a biopharmaceutical company committed to delivering innovative trea
Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update
01:20am, Thursday, 10'th Apr 2025
GENEVA, SWITZERLAND / ACCESS Newswire / April 10, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief), a biopharmaceutical company committed to delivering innovative tr
Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011
01:20am, Tuesday, 11'th Feb 2025
Patent Secures Protection for RLF-TD011 in Epidermolysis Bullosa Wound Treatment GENEVA, SWITZERLAND / ACCESS Newswire / February 11, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF) (OTC
Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US
01:20am, Wednesday, 22'nd Jan 2025
Sale of GOLIKE® Rights Outside the U.S. to Nutrisens Relief to Focus on R&D of Pipeline Assets and Licensing for Commercialized Products GENEVA, SWITZERLAND / ACCESS Newswire / January 22, 2025 / REL
Relief Therapeutics Provides Update on Potential Transaction with Renexxion
01:20am, Friday, 27'th Dec 2024
GENEVA, SWITZERLAND / ACCESSWIRE / December 27, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF) (OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to deliverin
Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial
01:20am, Monday, 16'th Dec 2024
Clinical Trial Demonstrates Superior Metabolic Control During Prolonged Fasting in PKU Patients Results Expected to Promote Awareness and Adoption of PKU GOLIKE ® GENEVA, SWITZERLAND / ACCESSWIRE / D
Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations
05:25pm, Friday, 13'th Dec 2024
Company to Maintain SIX Swiss Exchange Listing, U.S. ADR Program, and U.S. OTCQB Quotation GENEVA, SWITZERLAND / ACCESSWIRE / December 13, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF)
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
01:20am, Monday, 11'th Nov 2024
GENEVA, SWITZERLAND / ACCESSWIRE / November 11, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering
